NIR‐II fluorescent probes are powerful tools for advanced imaging, with performance governed by molar extinction coefficient (ε), quantum yield (Φ), and brightness (ε × Φ). However, achieving high brightness remains a major challenge. Here we report SCU‐OX‐Hex, a D–A–D probe with an O‐xanthene acceptor and an N‐alkylated aniline donor. Elongating the N‐alkyl chain enhances Φ and brightness while suppressing aggregation‐caused quenching. SCU‐OX‐Hex exhibits ε = 1.71 × 10 5 M −1 cm −1 , Φ = 0.57%, and a brightness of 974.7 M −1 cm −1 —among the highest reported for organic NIR‐II probes. In vivo, it enables high‐resolution imaging of the abdominal vasculature, the gastrointestinal tract, and tumor angiogenesis. In a lymph node metastasis model, it provides superior contrast and resolution compared with ICG, enabling precise intraoperative identification. This work establishes SCU‐OX‐Hex as a high‐performance NIR‐II agent and offers a broadly applicable design strategy for next‐generation probes.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: